Jaythari is indicated for the treatment of DMD, a rare and genetic disease that results in ongoing muscle weakness and degeneration.

The drugmaker has received the USFDA's final approval to manufacture a particular corticosteroid called Deflazacort to treat Duchenne muscular dystrophy.

Stocks including HCL Technologies, IRCON International, Zydus Lifesciences, Tata Power, Cyient, Indian Hotels, JK Cement, Havells and Macrotech Developers will be in the spotlight on Tuesday, April 15 ...

Explore the latest stock alerts: Macrotech, Reliance, Vedanta, Dr Reddy's, and more. Check out key developments today!

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg (USRLD: Emflaza ...

Ahmedabad: Pharma major, Zydus Lifesciences Limited has received final approval from the United States Food and Drug ...

Zydus Lifesciences has secured final approval from the US Food and Drug Administration (USFDA) to manufacture Jaythari (Deflazacort) tablets in four strengths - 6 mg, 18 mg, 30 mg, and 36 mg.

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) on Friday, April 11, announced that it has received final approval from the United ...

Shares of Tata Steel jumped nearly 6 percent in trade on Friday after global brokerage JPMorgan highlighted 500 million euro in potential cost savings from the company's transformation plans at its ...

Benchmark Indian indices surged on April 11, with Sensex rising over 1,300 points and Nifty 50 up nearly 2 percent following a relief rally on US President Trump's 90-day pause on tariffs, which is ...

Zydus Lifesciences Ltd - Announcement under Regulation 30 (LODR)-Press Release / Media Release ...